Text Size: a  |   a 

Molecules in Blood Could Be Biomarkers of MS Progression

January 30, 2017

MicroRNAs in the blood could serve as biomarkers to monitor the progression of MS, as well as help identify which mechanisms are at play in each patient, such as inflammation and tissue damage, according to new research.

The findings were reported in the study, “Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures Of Multiple Sclerosis Severity.” It was published in the journal JAMA Neurology.

MicroRNAs are tiny RNA molecules that can control gene expression and regulate protein production. They have the ability to bind to an mRNA molecule (a copy of the coding information required to produce a protein) and block production of a given protein. MicroRNAs can bind to many different mRNA molecules, which makes them powerful regulators.

Although microRNAs are produced within the cells, where they function, some can be secreted into several body fluids. They are highly resistant to degradation, so circulating microRNAs could be ideal biomarkers to follow the progression of certain diseases.

Karen Regev, MD, of Harvard Medical School, and her colleagues previously demonstrated that MS patients had a specific set of microRNAs in their blood, and that those molecules could be biomarkers to diagnose the disease. Using magnetic resonance imaging (MRI), they’ve now found that those microRNAs are correlated with brain and spinal damage.

READ MORE

https://multiplesclerosisnewstoday.com/2017/01/27/blood-micrornas-could-serve-as-biomarkers-for-monitoring-progression-of-multiple-sclerosis-study-says/